SMN2 and proximal spinal muscular atrophy: Risdiplam (EVRYSDI®) is a centrally and peripherally distributed, oral SMN2 pre‐mRNA splicing modifier,11 which has recently been approved by the FDA for the treatment of patients with SMA aged 2 months and older in the United States12 and is currently under HA review in the EU.